Nerviano Medical Sciences at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Nerviano Medical Sciences brings 2 presentations to ENA 2026 in Barcelona. Its posters cover new small molecules for AML and for HR-proficient cancers. NMS-812, a clinical-stage dual PERK and GCN2 modulator, works alone and with venetoclax/azacitidine in venetoclax-resistant AML, while highly potent RAD51 inhibitors show first-in-class potential.
| Organization | ENA 2026 Attendance |
|---|---|
Nerviano Medical Sciences Nerviano, Italy | |
Oncology drug discovery and development company with small-molecule and ADC programmes. | Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from Nerviano Medical Sciences
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction